Human Cytomegalovirus Infection Suppresses CD34+ Progenitor Cell Engraftment in Humanized Mice
Autor: | Rebecca Tempel, Felicia Goodrum, Daniel N. Streblow, Lindsey B. Crawford, Andrew D. Yurochko, Jay A. Nelson, Patrizia Caposio |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Microbiology (medical) Human cytomegalovirus progenitor cell viruses CD34 030230 surgery Microbiology Progenitor Cell Engraftment 03 medical and health sciences 0302 clinical medicine Virology Medicine Progenitor cell hematopoietic stem cell transplant lcsh:QH301-705.5 myelosuppression business.industry Brief Report Hematopoietic stem cell medicine.disease hematopoiesis virology 030104 developmental biology medicine.anatomical_structure surgical procedures operative humanized mice lcsh:Biology (General) human cytomegalovirus Humanized mouse Immunology Bone marrow Stem cell business |
Zdroj: | Microorganisms Microorganisms, Vol 8, Iss 525, p 525 (2020) |
ISSN: | 2076-2607 |
Popis: | Human cytomegalovirus (HCMV) infection is a serious complication in hematopoietic stem cell transplant (HSCT) recipients due to virus-induced myelosuppression and impairment of stem cell engraftment. Despite the clear clinical link between myelosuppression and HCMV infection, little is known about the mechanism(s) by which the virus inhibits normal hematopoiesis because of the strict species specificity and the lack of surrogate animal models. In this study, we developed a novel humanized mouse model system that recapitulates the HCMV-mediated engraftment failure after hematopoietic cell transplantation. We observed significant alterations in the hematopoietic populations in peripheral lymphoid tissues following engraftment of a subset of HCMV+ CD34+ hematopoietic progenitor cells (HPCs) within the transplant, suggesting that a small proportion of HCMV-infected CD34+ HPCs can profoundly affect HPC differentiation in the bone marrow microenvironment. This model will be instrumental to gain insight into the fundamental mechanisms of HCMV myelosuppression after HSCT and provides a platform to assess novel treatment strategies. |
Databáze: | OpenAIRE |
Externí odkaz: |